@article{b37e8d3f0c7d4fdea229fe5ddd087666,
title = "Testing and interpreting measures of ovarian reserve: a committee opinion",
abstract = "Ovarian reserve is defined as the number of oocytes remaining in the ovary, or oocyte quantity (oocyte number). Markers of ovarian reserve include hormone levels and sonographically measured features of the ovaries. These markers can be useful as predictors of oocyte yield following controlled ovarian stimulation and oocyte retrieval. However, they are poor predictors of reproductive potential independently from age. This document replaces the document of the same name last published in 2012 (Fertil Steril 2012;98:1407–15).",
author = "{Practice Committee of the American Society for Reproductive Medicine} and Alan Penzias and Ricardo Azziz and Kristin Bendikson and Tommaso Falcone and Karl Hansen and Micah Hill and William Hurd and Sangita Jindal and Suleena Kalra and Jennifer Mersereau and Catherine Racowsky and Robert Rebar and Richard Reindollar and Shannon, {Chevis N.} and Anne Steiner and Dale Stovall and Cigdem Tanrikut and Hugh Taylor and Belinda Yauger",
note = "Funding Information: This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Practice Committee and the Board of Directors of the ASRM have approved this report. This document was reviewed by ASRM members and their input was considered in the preparation of the final document. The following members of the ASRM Practice Committee participated in the development of this document: Alan Penzias, M.D(Chair). Ricardo Azziz, M.D. M.P.H. M.B.A. Kristin Bendikson, M.D. Tommaso Falcone, M.D. Karl Hansen, M.D. Ph.D. Micah Hill, D.O. William Hurd, M.D. MPH, Sangita Jindal, Ph.D. Suleena Kalra, M.D. M.S.C.E. Jennifer Mersereau, M.D. Catherine Racowsky, Ph.D.: Robert Rebar, M.D. Richard Reindollar, M.D. Chevis N. Shannon, Dr.P.H. M.P.H. M.B.A. Anne Steiner, M.D. M.P.H. Dale Stovall, M.D. Cigdem Tanrikut, M.D. Hugh Taylor, M.D. and Belinda Yauger, M.D. The Practice Committee acknowledges the special contribution of Amber Cooper, M.D. M.S.C.I. and Violet Klenov, M.D. in the preparation of this document. All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document. Publisher Copyright: {\textcopyright} 2020 American Society for Reproductive Medicine",
year = "2020",
month = dec,
doi = "10.1016/j.fertnstert.2020.09.134",
language = "English (US)",
volume = "114",
pages = "1151--1157",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",
}